Moleculin Biotech is trading at $0.44 (+7.23%) as shares stage a recovery following a sharp multi-day collapse triggered by a $9.3 million public offering and resulting dilution pressure.
- The stock hit a low of $0.41 on August 4 after the company priced its offering at $0.75 per share with heavy warrant coverage, leading to a significant selloff.
- No new company-specific catalyst has been identified for today's move; the rebound appears to be a technical bounce from oversold levels amid broader sector strength, with the XBI up 2.02%.